Publications

At Visible Analytics, we foster a learning culture, support research initiatives and encourage personal development and professional growth. We pride ourselves on our ever-growing roster of publications, whether of client-sponsored, academic or in-house studies. These include papers disseminating cutting-edge methodologies and their application to a wide range of diseases and conditions. 


Systematic review and evidence synthesis

Freeman SC, Sutton AJ, Cooper NJ, Gasparini A, Crowther MJ, Hawkins N. Bayesian pairwise meta-analysis of time-to-event outcomes in the presence of non-proportional hazards: A simulation study of flexible parametric, piecewise exponential and fractional polynomial models. Res Synth Methods. 2024.

Chase DM, Mahajan A, Scott DA, Hawkins N, Kalilani L. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review. Int J Gynecol Cancer. 2023;33(10):1602-11.

Thompson, J. C., Mahajan, A., Scott, D. A., & Gairy, K. (2022). The Economic Burden of Lupus Nephritis: A Systematic Literature Review. Rheumatology and Therapy, 9(1), 25–47.

Thompson, J. C., Chalet, F. X., Manalastas, E. J., Hawkins, N., Sarri, G., & Talbot, D. A. (2022). Economic and Humanistic Burden of Cerebral Vasospasm and Its Related Complications after Aneurysmal Subarachnoid Hemorrhage: A Systematic Literature Review. Neurology and Therapy, 11(2), 597–620.

Singh, J., Gsteiger, S., Wheaton, L., Riley, R. D., Abrams, K. R., Gillies, C. L., & Bujkiewicz, S. (2022). Bayesian network meta-analysis methods for combining individual participant data and aggregate data from single arm trials and randomised controlled trials. BMC Medical Research Methodology, 22(1), 186.

Hannigan, L. J., Phillippo, D. M., Hanlon, P., Moss, L., Butterly, E. W., Hawkins, N., Dias, S., Welton, N. J., & McAllister, D. A. (2022). Improving the Estimation of Subgroup Effects for Clinical Trial Participants with Multimorbidity by Incorporating Drug Class-Level Information in Bayesian Hierarchical Models: A Simulation Study. Medical Decision Making: an international journal of the Society for Medical Decision Making, 42(2), 228–240.

Bujkiewicz, S., Singh, J., Wheaton, L., Jenkins, D., Martina, R., Hyrich, K. L., & Abrams, K. R. (2022). Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: bayesian evidence synthesis with target trial emulation. Journal of clinical epidemiology, 150, 171–178. Advance online publication.

Ribero, V. A., Daigl, M., Martí, Y., Gorni, K., Evans, R., Scott, D. A., Mahajan, A., Abrams, K. R., & Hawkins, N. (2022). How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. Journal of Comparative Effectiveness Research, 11(5), 347–370.

Garcia Sanchez, J. J., Thompson, J., Scott, D. A., Evans, R., Rao, N., Sörstadius, E., James, G., Nolan, S., Wittbrodt, E. T., Abdul Sultan, A., Stefansson, B. V., Jackson, D., & Abrams, K. R. (2022). Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. Advances in Therapy, 39(1), 193-220.

Owen, R. K., Bujkiewicz, S., Tincello, D. G., & Abrams, K. R. (2020). Multivariate network meta-analysis incorporating class effects. BMC Medical Research Methodology, 20(1), 184.

Statistical Analysis

Chase DM, Mahajan A, Scott DA, Hawkins N, Kalilani L. The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis. BMC Womens Health. 2024;24(1):179.

Broomfield J, Abrams KR, Freeman S, Latimer N, Rutherford MJ, Crowther MJ. Modeling the multi-state natural history of rare diseases with heterogeneous individual patient data: A simulation study. Stat Med. 2024;43(1):184-200.

Hawkins, N., Muszbek, N., Evans, R., Dequen-O’Byrne, P., Jones, T., & McNamara, L. (2022). Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome. Journal of comparative effectiveness research, 11(11), 805–813.

Freeman, S. C., Cooper, N. J., Sutton, A. J., Crowther, M. J., Carpenter, J. R., & Hawkins, N. (2022). Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network. Statistical methods in medical research, 31(5), 839–861.

Evans, R., Hawkins, N., Dequen-O’Byrne, P., McCrea, C., Muston, D., Gresty, C., Ghate, S. R., Fan, L., Hettle, R., Abrams, K. R., de Bono, J., Hussain, M., & Agarwal, N. (2021). Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). Targeted oncology, 16(5), 613–623.

Economic Modelling

Muszbek N, Remak E, Xin Q, McNamara L, Jones T. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma. J Comp Eff Res. 2023 Jul;12(7):CER.

Gal P, Feldmajer G, Augusto M, Gani R, Hook E, Bullement A, Philips Z, Smith I. De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and Validation. Pharmacoeconomics. 2023 Dec;41(12):1629-1639.

Mendes D, Chapman R, Aruffo E, Gal P, Nguyen JL, Hamson L, Di Fusco M, Czudek C, Yang J. Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance. Expert Rev Vaccines. 2023 Jan-Dec;22(1):90-103.

Muszbek, N., Evans, R., Remak, E., Brennan, V. K., Colaone, F., Shergill, S., Ross, P., & Mullan, D. (2022). Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert review of pharmacoeconomics & outcomes research, 22(1), 147–154.

Muszbek, N., Remák, E., Evans, R., Brennan, V. K., Colaone, F., Shergill, S., Mullan, D., & Ross, P. J. (2021). Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma. Future oncology (London, England), 17(9), 1055–1068.                                                                                                                                                                                                                                                                  

Chandler C, Folse H, Gal P, Chavan A, Proskorovsky I, Franco-Villalobos C, Yang Y, Ward A. Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study. J Mark Access Health Policy. 2021 Jun 3;9(1):1922163.

Torres A, Bassetti M, Welte T, Rivolo S, Remák E, Peral C, Charbonneau C, Hammond J, Ansari W, Grau S. Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. Journal of Medical Economics 2020;23(2):148-155.

Barra M, Remák E, Liu DD, Xie L, Abraham L, Sadosky AB. A cost-consequence analysis of parecoxib and opioids vs opioids alone for postoperative pain: Chinese perspective. Clinicoecon Outcomes Res. 2019 Feb 22;11:169-177.

Muszbek N, Proudfoot C, Fournier M, Chen CI, Kuznik A, Kiss Z, Gal P, Michaud K. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. J Manag Care Spec Pharm. 2019 Nov;25(11):1268-1280.

Real World Evidence

Broomfield J, Abrams K, Latimer N, Guglieri M, Rutherford M, Crowther M. Natural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink. Brain Behav. 2023;13(12):e3331.

Lyons J, Akbari A, Abrams KR, Azcoaga Lorenzo A, Ba Dhafari T, Chess J, et al. Trajectories in chronic disease accrual and mortality across the lifespan in Wales, UK (2005-2019), by area deprivation profile: linked electronic health records cohort study on 965,905 individuals. Lancet Reg Health Eur. 2023;32:100687.

Remák, E., Hawkins, N., Jones T, Otlez M, Twigger R, Prince M. Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-worlds evidence and MAVORIC phase 3 trial data. Eur J Cancer 2021 Oct(Suppl 1):S18.     

Heggie, R., Chappell, F., Crawford, F., Martin, A., Gupta, S., Hawkins, N., Horne, M., Leese, G. P., & Lewsey, J. (2020). Complication rate among people with diabetes at low risk of foot ulceration in Fife, UK: an analysis of routinely collected data. Diabetic medicine: a journal of the British Diabetic Association, 37(12), 2116–2123.

Jenkins, D. A., Hussein, H., Martina, R., Dequen-O’Byrne, P., Abrams, K. R., & Bujkiewicz, S. (2021). Methods for the inclusion of real-world evidence in network meta-analysis. BMC medical research methodology, 21(1), 207.

Torlinska, B., Hazlehurst, J. M., Nirantharakumar, K., Thomas, G. N., Priestley, J. R., Finnikin, S. J., Saunders, P., Abrams, K. R., & Boelaert, K. (2021). wEight chanGes, caRdio-mEtabolic risks and morTality in patients with hyperthyroidism (EGRET): a protocol for a CPRD-HES linked cohort study. BMJ open, 11(10), e055219.

Teece, L., Gray, L. J., Melbourne, C., Orton, C., Ford, D. V., Martin, C. A., McAllister, D., Khunti, K., Tobin, M., John, C., Abrams, K. R., Pareek, M., & UK-REACH Study Collaborative Group (2021). United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): a retrospective cohort study using linked routinely collected data, study protocol. BMJ open, 11(6), e046392.

Health technology assessment

Szabo SM, Hawkins NS, Germeni E. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH. Int J Technol Assess Health Care. 2023;40(1):e6.

Morga A, Latimer NR, Scott M, Hawkins N, Schlichting M, Wang J. Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum. Value Health. 2023;26(2):234-42.

Bouttell, J., Briggs, A., & Hawkins, N. (2021). The thorny issue of value alignment: how development-focused health technology assessment can help find win-win situations for patients and healthcare systems and commercial investors. International journal of technology assessment in health care, 37(1), e57.

Bouttell, J., Briggs, A., & Hawkins, N. (2020). A different animal? Identifying the features of health technology assessment for developers of medical technologies. International journal of technology assessment in health care, 1–7. Advance online publication.

Beca J, Husereau D, Chan KKW, Hawkins NS, Hoch JS. Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment. PharmacoEconomics. 2018;36(1):7-15.

Fletcher C, Chuang-Stein C, Paget M-A, Reid C, Hawkins NS. Subgroup analyses in cost-effectiveness analyses to support health technology assessments. Pharmaceutical Statistics. 2014;13(4):265-74.